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Abstract
Study design Pilot, multicentre randomised clinical trial
(RCT).
Objectives Assess viability of performing a definitive
RCT and compare preliminary effects of movement pattern
training (MoveTrain) and strengthening/flexibility (Standard)
to improve function in people with chronic hip-related
groin pain (HRGP).
Background To determine the best physical therapist-
led intervention for patients with HRGP, we must
understand treatment effects of different treatment
modes.
Methods Forty-six patients (17M:29F; 29±5.3 years;
body mass index 25.6±6.3 kg/m2) with HRGP were
randomised. MoveTrain included task-specific training
to optimise biomechanics during daily tasks. Standard
included strengthening/flexibility. Treatment included 10
visits/12 weeks and home exercise programme (HEP).
Primary outcomes for feasibility were recruitment,
retention, treatment adherence and treatment fidelity.
Secondary outcomes were patient-reported function (Hip
disability and Osteoarthritis Outcome Score (HOOS)), lower
extremity kinematics and hip muscle strength.
Results We achieved target recruitment, and retention
was excellent (91%). Patient session attendance was high
(93%); however, reported HEP adherence (62%) was lower
than expected. Physical therapists’ adherence to treatment
protocols was high (90%). Patients demonstrated high
treatment receipt; 91% of exercises performed were
rated independent. Both groups demonstrated clinically
important improvements in function (HOOS) and muscle
strength; however, there were no between-group
differences (HOOS subscales, p≥0.13, strength, p≥0.34).
Compared with Standard, MoveTrain demonstrated greater
reductions in hip adduction (p=0.016) and pelvic drop
(p=0.026) during a single leg squat. No adverse events
were noted.
Conclusion Our experience in completing this RCT
confirmed that a larger, multicentre RCT is feasible and
highlighted modifications we will implement to optimise
the future RCT.
Trial registration number NCT02913222.

What are the new findings
►► Using our methods, a large, multicentre randomised

clinical trial (RCT) to compare MoveTrain and
Standard treatment for patients with hip-
related
groin pain (HRGP) is feasible as demonstrated by
high retention, patient adherence and treatment
fidelity.
►► Preliminary findings related to patient-reported outcomes, kinematics and strength suggest that rehabilitation may be appropriate for patients with HRGP;
however, further study is needed.
►► A better understanding of treatment effects of rehabilitation will allow us to better compare surgical
and non-surgical treatments, thus ultimately leading
to the ability to better match patients to treatment.

Introduction
Hip-
related groin pain (HRGP) results in
significant pain and activity limitations among
young to middle aged adults. Hip disorders
proposed to contribute to HRGP include
femoroacetabular impingement syndrome
(FAIS), acetabular dysplasia, labral tears
and injury to other intra-articular structures.
Additionally, acetabular dysplasia and FAIS
are associated with development of hip osteoarthritis.1 2 It is important to intervene early
and provide effective treatment to improve
pain and function among those with HRGP
and potentially prevent or delay hip osteoarthritis (OA).
While significant literature exists related
to surgical interventions, evidence related
to physical therapist (PT)-
led intervention
remains sparse.3–5 Three randomised clinical trials (RCTs) were recently published
comparing arthroscopic surgery to PT-
led
intervention for patients with FAIS. Two
studies6 7 reported greater improvement
among those who received surgery compared
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with PT-
led intervention, but one study reported no
differences between the two interventions.8 These mixed
findings may be partially due to limited evidence available to inform PT-led intervention. PT-led interventions
described in previous RCTs were based primarily on
expert opinion, resulting in intervention that is multimodal and non-
standard, thus limiting our ability to
make conclusions about the effect of any one treatment.
To ultimately determine comparative effectiveness of
PT-led intervention and surgical intervention of HRGP,
we must first determine the best PT-led intervention by
understanding the effects of different treatments. We
compared two PT-led interventions, movement pattern
training (MoveTrain) and traditional strengthening and
flexibility (Standard).
The goal of MoveTrain is to reduce hip joint stress by
optimising biomechanics during functional tasks. The
key element of MoveTrain is task-specific instruction to
correct abnormal movement patterns during daily activities. In our previous proof-of-concept study, we noted that
patients with HRGP who participated in MoveTrain were
able to reduce hip adduction motion during a single leg
squat,9 and this reduction was associated with improved
patient-reported function.9 10 Given resources required
to conduct a larger RCT to definitively determine MoveTrain effects, we designed a pilot, multicentre RCT to
assess the viability of performing a definitive RCT.
The primary purpose of this study was to determine
patient retention and treatment adherence and to demonstrate treatment fidelity among treatment providers and
patients at both clinical sites. Our secondary purpose
was to compare the preliminary effects of MoveTrain to
Standard on patient-reported function, lower extremity
kinematics (targeted by MoveTrain) and hip muscle
strength (targeted by Standard).
Methods
Study design, setting and patient involvement
This study was a pilot, multicentre RCT (figure 1). Data
collection and treatment occurred at The Movement
Science Research Center at Washington University’s
Program in Physical Therapy and The Physical Therapy
– Clinical and Translational Research Center at the
University of Pittsburgh. Washington University served
as the coordinating centre and single site institutional
review board (IRB). This study was approved by Human
Research Protection Offices of Washington University and University of Pittsburgh. All patients signed
an informed consent statement prior to participating.
Patients were not involved in the design, recruitment or
conduct of the study.
Manual of operations (MOP) development and training
An MOP was developed to document standard methods
for all study components. To optimise treatment fidelity,
we used the treatment fidelity framework developed
by National Institutes of Health’s Behavioral Change
Consortium.11 12 Active ingredients believed to affect
2

patient outcomes for each treatment arm were identified
and operationally defined. Each treatment protocol was
reviewed by experts at both sites to ensure it reflected
the underlying theory of its respective approach. The
first author led onsite training for examiners (n=2) and
treating PTs (n=5); all were PTs with 6–27 years of experience. Training included review and discussion of the
MOP, patient scenario role plays to demonstrate assessment and treatment concepts and discussion to identify
barriers to study protocol performance and patient treatment adherence. Training time totalled 16 hours per site.
Participants
Patients were recruited between January 2017 and
February 2018, from healthcare clinics; research
volunteer databases; social media; and other written
communications. To be eligible, patients had to be 15–40
years old; report deep hip joint or anterior groin pain
that was reproduced with flexion, adduction, internal
rotation impingement test13; report pain ≥3/10 and
present ≥3 months; and demonstrate functional limitation with modified Harris Hip Score14 <90. Exclusion
criteria included previous hip surgery, fracture, infection or pain due to high impact trauma; diagnosed with
Legg-
Calve-
Perthes disease or slipped capital femoral
epiphysis; inflammatory disease; neurological involvement affecting balance; pain, numbness or tingling that
radiates into thigh; pregnancy; and screening tests indicating hip pain was referred from the spine.
Assessment (baseline and post-treatment)
Patients who passed initial screening were scheduled for
clinical examination, which included assessment of final
screening criteria and, if the patient was determined to
be eligible, baseline assessment. Patients completed self-
report questionnaires and participated in assessment of
movement patterns and hip strength. Patients were then
randomised into MoveTrain or Standard. Thirteen weeks
after enrolment, patients returned for post-
treatment
testing.
Treatments
Treatments were delivered according to the Template
for intervention Description and Replication Guidelines.15 Treatment for both groups included 10
supervised sessions over 12 weeks and daily home exercise programme (HEP). Both treatment arms included
assessment of patient goals, patient education and HEP
instruction. Patient education focused on patient-specific
tasks, which were identified using the Patient Specific
Functional Scale (PSFS).16 A brief description of each
treatment arm is provided below.
Movement pattern training (MoveTrain) (online
supplementary appendix A): treatment focus was on task-
specific training to improve lower extremity kinematics
during functional and patient-
specific tasks. Patient
education included instruction in abnormal movement
patterns and methods to optimise movement patterns
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Figure 1 Study flow diagram. CONSORT flow diagram adapted. CONSORT, Consolidated Standards of Reporting Trials; WU,
Washington University; UP, University of Pittsburgh. *inclusion criteria categories are not mutually exclusive.

during each task. Exercises included repeated practice
of tasks using optimised movement patterns. Verbal cues
and visual aids were used to assist the patient. Based on
patient performance, task difficulty was progressed by
varying repetitions performed, increasing load or speed
or changing support surface.
Standard rehabilitation (Standard) (online supplementary appendix B): treatment focus was on progressive lower
extremity and trunk strengthening and lower extremity
flexibility. Patient education included instruction to
modify intensity, frequency or duration of patient-specific
tasks. Strengthening and flexibility exercises prescribed
were selected using current clinical practice guidelines17
and previous reports.5 18 Each patient was progressed by
increasing repetitions performed or increasing load.
Primary outcomes: feasibility
Primary outcomes were related to feasibility of the larger
trial. Recruitment rate was defined as the number of

patients deemed eligible who agreed to participation.
Retention rate was defined as the percentage of those
who completed post-
treatment testing. Patient treatment session adherence was defined as the percentage
of supervised visits attended. Patient HEP adherence was
defined as the percentage of days the patient reported
completing their HEP.
To assess treatment fidelity,11 12 we assessed PT treatment delivery and patient treatment receipt. Treatment
delivery was assessed using prestudy assessment and
poststudy chart reviews to assess protocol adherence.
Prestudy assessment included a written exam and role-
played scenarios.19 For role-played scenarios, a checklist
was used to document standard performance of active
ingredients for each treatment. To assess protocol adherence, a PT who was not involved in providing treatment
completed chart reviews. A standard form was used to
identify if performance of active ingredients for each
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treatment arm was documented. Protocol adherence was
scored as percentage of active ingredients completed.
In addition to our a prior feasibility outcomes, we
assessed patient treatment receipt, which relates to
ability to understand key treatment concepts, and ability
to independently perform tasks.11 12 Using our previously
published methods,19 treatment receipt was scored by
the treating PT as the proportion of exercises the patient
performed independently.
Secondary outcomes: preliminary effectiveness
Preliminary effectiveness outcomes determined a priori
were the Hip dysfunction and Osteoarthritis Outcome
Score (HOOS) subscales of activities of daily living (ADL)
and symptoms,20 hip adduction angle during a single leg
squat and hip muscle strength.
Patient-reported outcome measures
The HOOS is a reliable21–23 and valid21 23 hip-specific
patient-reported outcome used to quantify activity limitations among those with hip disorders. The values for
the HOOS subscales, including pain, symptoms, ADLs,
sport and recreation (Sport) and quality of life range
from 0 to 100 with higher scores indicating higher levels
physical function. The established values for minimum
important change (MIC) for people with HRGP who
have undergone arthroscopic surgery are 8, 9, 9, 6, 10
and 11, respectively.23 Values for MIC for non-surgical

management are not available. In addition, we collected
PSFS16; Patient-Reported Outcomes Measurement Information System (PROMIS) Scores24 25; and Pain Numeric
Rating Scale.26 Information for the additional measures
are provided in table 4.
Kinematics
A digital camera was used to capture two-dimensional
motion while the patient completed three single leg
squats.27 figure 2 demonstrates the variables of interest
including hip adduction, pelvic tilt (obliquity/drop)
and trunk lean (ipsilateral lean). Values of three trials
were averaged for each variable. Inter-rater reliability of
all measures among our group was excellent (intraclass
correlation (ICC3,3:) >0.98, SE of measurements <1°).
Muscle strength
A microFET3 hand-held dynamometer (Hogan Health
Industries, Salt Lake City, Utah, USA) was used to assess
hip muscle strength of hip external rotators, internal
rotators, abductors, adductors, flexors and extensors.
Make tests28 were used, incorporating a strap for resistance. After a practice trial, three maximal trials were
performed. Force values of three trials were averaged and
used to calculate torque, then normalised by weight and
height.29 Strength was not a primary outcome, and this
study was funded by an R21 mechanism, which provides
limited resources. Performing an inter-
rater reliability

Figure 2 (A) Initial position. Line A is drawn between the anterior superior iliac spine (ASIS) markers and is the initial position
of the pelvis. Line B is drawn from the sternal marker to the midpoint of line A and is the initial position of the trunk. (B) Final
depth of squat. Line C is drawn between the ASIS markers and is the final position of the pelvis. Line D is drawn from the
sternal marker to the midpoint of line C and is the final position of the trunk. Line E is drawn from the ASIS marker to the femur
marker on the weight-bearing leg and is the final position of the femur. (C) Angle measurement. Hip adduction angle is defined
by lines C and E. Positive values indicate hip adduction; pelvic excursion is defined by lines A and C. Negative values indicate
a pelvic tilt in which the non-weight-bearing side is lowering; trunk excursion is defined by lines B and D. Positive values
indicate the trunk is leaning towards the weightbearing limb.
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study of each secondary outcome was simply not feasible
within this mechanism. A previous study using similar
methods reported high test–retest reliability, ICCs >0.82.
A priori criteria for success
A priori criteria for success included: (1) 46 participants recruited; (2) 90% retention9; (3) 90% adherence
to attending treatment sessions; (4) 80% adherence to
HEP; and (5) treatment providers scoring at least 95%
on prestudy examination and 80% protocol adherence.
We hypothesised MoveTrain would demonstrate
greater improvement in HOOS and greater reduction
in peak hip adduction during functional tasks compared
with Standard, despite possibly demonstrating less hip
strength.
Pilot trial sample size
Sample size for primary outcomes was based on precision and assumed that observed rates of adherence and
retention would be at least 90%.9 With a sample size of
46 (23/group), 95% CI around observed rates of adherence and retention were expected to be 78%–96% (ie,
within 9% of the true rate). The study was designed to
estimate effect sizes for treatment outcomes; therefore,
the study was 80% powered to detect large effect sizes of
0.9 or above.
Randomisation
Patients were randomised to treatment in 1:1 ratio
stratified by site, sex and HOOSSymptoms subgroup
(determined from median split of preliminary data).
Within each stratum, patients were allocated using a
variable block size. Randomisation sequences were
generated a priori using a formal probability model and
were elicited from the data capture system. Given the
nature of treatment, it was not possible to blind treating
PTs or patients to treatment assignment. Study personnel
performing assessments and kinematic measurements
were blinded to group.
Statistical analysis
Fisher’s exact test compared retention and patient adherence to treatment session rates by site and by group.
Patient adherence to HEP, therapists’ treatment delivery
and patient treatment receipt were compared by site and
group using Wilcoxon’s test.
Data collected at pretest and post-test were analysed
with analysis of covariance where post-test was the dependent variable, pretest was the covariate and treatment
group was the independent variable that tests the null
hypothesis that after adjusting for pretest, post-test is not
significantly different across treatment groups. A general
linear model was used when residuals were normally
distributed, and homogeneity of regression lines assumption was satisfied, otherwise non-parametric covariance
analysis30 was used. Multinomial generalised estimating
equations was used to analyse ordinal pain numeric
rating scales.

Results
Primary outcomes: feasibility
Table 1 provides baseline characteristics of study groups.
Overall results related to study feasibility along with site-
specific and treatment group-specific comparisons are
provided in table 2.
Recruitment and Retention Rate
A flow diagram of patient recruitment and retention are
provided in figure 1. Overall, 42/46 (91%; 95% CI 83%
to 99%) of patients completed post-
treatment testing
(table 2).
Treatment adherence
Overall, 43/46 (93%; 95% CI 86% to 100%) of patients
attended at least 90% of their sessions. The 43 patients
who completed at least 90% of supervised sessions
reported HEP completion on 62% (range 9%–97%) of
days.
PTs’ treatment delivery
All providers scored >95% on written exam and role-
played scenarios. Chart reviews resulted in data for
132 treatment visits for the 45 patients who completed
at least one treatment visit. Overall, the proportion of
active ingredients completed by PTs was 90% (range
60%–100%).
Patients’ treatment receipt
Overall, the proportion of exercises rated independent
was 91% (range 18%–100%).
Protocol deviations
We had nine protocol deviations. Two patients had
their baseline HOOSSymptom score entered into the
data system incorrectly, resulting in each patient being
randomised to treatment within an incorrect stratum. Due
to personal scheduling issues, four patients completed
post-treatment examination before 13 weeks and three
completed post-treatment examination after 16 weeks.
Safety
No unexpected adverse events were noted. Twenty-seven
patients reported discomfort in hip, knee or spine with
performance of at least one exercise (table 3). More
patients in Standard reported pain with at least one exercise compared with MoveTrain (85% vs 45%, respectively
p=0.008). Each reported exercise was modified by the
treating PT.
Secondary outcomes: preliminary effectiveness
Both groups demonstrated improvements in all HOOS
subscales; however, there were no between-
group
differences (table 4). Both groups also demonstrated
similar improvements in PSFS, PROMIS scores and
Pain Numeric Rating scales. MoveTrain demonstrated
a greater reduction in hip adduction and pelvic tilt
(drop) during the single leg squat compared with
Standard (table 5). Both groups demonstrated similar
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Table 1 Demographics for all enrolled patients and patients who provided post-test data by treatment group (n=46)
Patients providing post-test data, by treatment group

Variable

All enrolled
Patients
n=46

All
n=42

MoveTrain
n=22

Standard
n=20

Age (year), mean±SD
(range)
Gender, n (%)

29.0±5.3
(17–39)
 

28.9±5.2
(17–39)
 

27.6±5.0
(17–37)
 

30.2±5.2
(22–39)
 

 Male

17 (37)

17 (40)

9 (41)

8 (40)

 Female

29 (63)

25 (60)

13 (59)

12 (60)

Race, n (%)

 

 

 

 

 American Indian or Alaska Native,
White

1 (2)

1 (2)

1 (5)

0 (0)

 Asian

1 (2)

1 (2)

1 (5)

0 (0)

 Asian, White

1 (2%)

1 (2)

1 (5)

0 (0)

 Black or African-American

4 (9)

4 (10%

4 (18)

0 (0)

 White

39 (85)

35 (83)

15 (68)

20 (100)

Hispanic or Latino

 0 (0)

 0 (0)

 0 (0)

 0 (0)

Not Hispanic or Latino

46 (100)

42 (100)

22 (100)

20 (100)

Ethnicity, n (%)

Education, n (%)

 

 

 

 

 9th–11th grade

1 (2)

1 (2)

1 (5)

0 (0)

 12th grade

1 (2)

1 (2)

0 (0)

1 (5)

 Some college/associate degree

5 (11)

3 (7)

3 (14)

0 (0)

 College degree

26 (57)

25 (60)

13 (59)

12 (60)

 Non-doctoral graduate degree

9 (20)

8 (19)

4 (18)

4 (20)

 Doctoral degree

4 (9)

4 (10)

1 (5)

3 (15)

Study limb, n (%)

 

 

 

 

 Left

21 (46)

19 (45)

10 (45)

9 (45)

 Right

25 (54)

23 (55)

12 (55)

11 (55)

Pain: involved side, n (%)

 

 

 

 

 Left

15 (33)

13 (31)

8 (36)

5 (25)

 Right

15 (33)

13 (31)

6 (27)

7 (35)

 Bilateral

16 (35)

16 (38)

8 (36)

8 (40)

Measured BMI (kg/m2), mean±SD
(range)

25.6±6.3
(17.9–46.1)

25.2±6.0
(17.9–46.1)

24.9±6.1
(17.9–41.8)

25.6±6.1
(20.2–46.1)

UCLA*, median (range)

10 (3–10)

10 (3–10)

9.5 (3–10)

10 (4–10)

Pain report,
median
 (range)

 

 

 

 

 Pain duration (year)

2.0
(0.3–17.0)

2.0
(0.3–17.0)

1.8
(0.3–12.0)

3.0
(0.3–17.0)

 Average pain†
 Worst pain†

3 (1–9)
6 (2–10)

3 (1–9)
6 (2–10)

4 (1–9)
6 (2–9)

3 (1–8)
5.5 (3–10)

*Patients are asked to rate their activity level over the previous 6 months. 10=regularly participates in impact sports; 1=wholly inactive,
dependent on others.
†Pain rated by patients using a verbal numerical pain rating scale. 0=no pain; 10=worst pain imaginable.
BMI, body mass index; MoveTrain, movement pattern training group; UCLA, University of California Los Angeles Activity Score.
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Table 2 Summary of results for primary outcomes related to study feasibility
Patients, by site

Patients, by treatment group

Variable

All
n=46

Primary
n=30

Partner
n=16

P

MoveTrain
n=23

Standard
n=23

P

Retention rate, n (%)*

42 (91)

30 (100)

Patient adherent to treatment
session attendance, n (%)‡

43 (93)

30 (100)

12 (75)

0.01†

22 (96)

20 (87)

0.61†

13 (81)

0.04†

21 (91)

22 (96)

1.0†

All
n=43§

Primary
n=30§

Partner
n=13§

P

MoveTrain
n=21§

Standard
n=22§

HEP adherence, median %
(range)¶

P

62
(9–97)

62
(18–95)

63
(9–97)

0.50**

61
(18–85)

75
(9–97)

0.22**

Patient treatment receipt,
median %
(range)††

91
(18–100)

92
(68–100)

83
(18–98)

0.47**

88
(18–100)

93
(81–100)

0.05**

All
n=45‡‡

Primary
n=30‡‡

Partner
n=15‡‡

MoveTrain
n=30‡‡

Standard
n=15‡‡

90
(60–100)

92
(73–100)

90
(60–100)

90
(67–100)

Active ingredients for treatment 90
delivery, median % (range)§§
(60–100)

P

<0.01**

P

0.83**

*Retention rate is defined as the percentage of those enrolled at baseline who completed testing after treatment.
†Fisher’s exact test for group comparison.
‡Treatment session attendance was documented by the physical therapist. The variable for treatment session attendance is the number of patients who attended
at least 90% (9 of 10) of their sessions.
§Number of patients completing at least nine supervised visits.
¶HEP adherence: participants were instructed to perform their HEP one time per day. The variable for HEP adherence was calculated as the total number of days
reported by the participant to have completed the prescribed exercises, summed over the entire treatment period and divided by the total number of treatment
days.
**Wilcoxon’s test.
††The total number of exercises the physical therapist reviewed and the total number of those exercises they rated as independent were each summed across all
treatment visits to derive the per cent of exercises rated as independent across the entire treatment (Σ independent / Σ reviewed * 100).
‡‡Number of patients who completed at least one supervised treatment visit.
§§Treatment delivery assessed using chart reviews to determine if the active ingredients of the treatment was provided. The variable for treatment delivery is the
proportion of active ingredients completed and documented by the treatment physical therapists for 132 treatment visits.
HEP, home exercise programme; MoveTrain, movement pattern training group.

increases in strength after treatment ranging from 6%
to 16% (table 5).
Discussion
We have established feasibility of completing a large,
multicentre RCT to compare effectiveness of MoveTrain
to Standard. We met our target enrolment and retention
rate. Patient adherence to treatment session attendance
was high. however, patient-reported adherence to HEP
was lower than expected. Regarding treatment fidelity,
we demonstrated high rates of treatment delivery among
PTs and treatment receipt among patients. Our preliminary results related to secondary outcomes suggest both
Table 3 The number of patients who reported pain or
discomfort with at least one exercise during treatment
Variable*

MoveTrain

Standard

Total

13
1

20
1

Hip
Knee

7

Lumbar spine

1

1

Hip and lumbar spine

1

1

Hip and knee
Total

1
10

3
17

Exercises were modified by the treating physical therapist.
*Each number represents one participant.
MoveTrain, movement pattern training group.

4
27

MoveTrain and Standard resulted in clinically significant improvements in patient-
reported outcomes and
hip muscle strength; however, only those in MoveTrain
showed improvement in kinematics.
Feasibility
We were able to meet our recruitment goals within
13 months of initiating recruitment. This suggests
our recruitment methods would result in an estimated 177 patients for a 5-year project. Our retention
rate for post-treatment testing was 91%, higher than
the 80% follow-up required for a high-quality RCT.31
We provided compensation for testing sessions and
treatment free of charge, which may have increased
retention. Additionally, there was frequent contact
between study personnel and patients, including weekly
treatment sessions and multiple communications with
research coordinators.
Treatment session attendance was high, indicating
feasibility of weekly supervised sessions. Patient self-
reported HEP adherence was lower than hypothesised.
Based on informal discussions and written communications, patients reported difficulty completing all
exercises every day and suggested the HEP be modified. Despite lower than expected HEP adherence,
patients in both groups demonstrated improvements in
HOOS and treatment-targeted mechanism, kinematics
and strength. Decreasing HEP frequency may result in
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Table 4 Summary of results for patient-reported outcome measures (n=42)
Pretest
Mean±SD

Post-test
Mean±SD

Within-group
change*
Mean±SD

Adjusted immediate
treatment effect†
Mean (95% CI)

P value‡

 MoveTrain (n=22)

66.6±14.9

84.7±13.5

18.1±12.9

−2.75 (−8.66 to 3.16)

0.35

 Standard (n=20)

70.3±12.0

89.3±8.7

19.0±9.6

 MoveTrain (n=22)

63.2±16.6

78.0±14.1

15.0±13.2

−5.55 (−13.10 to 1.99)

0.14

 Standard (n=20)

68.8±15.5

86.3±13.5

17.5±16.2

 MoveTrain (n=22)

79.5±15.0

92.0±11.2

12.5±11.0

−2.20 (−6.51 to 2.11)

0.32A

 Standard (n=20)

83.4±14.7

95.7±6.2

12.4±11.8

 MoveTrain (n=22)

58.5±20.0

83.0±16.4

24.4±18.1

−3.69 (−11.74 to 4.36)

0.36

 Standard (n=20)

69.1±17.6

90.6±11.2

21.6±15.6

 MoveTrain (n=22)

55.1±14.8

68.2±16.8

13.1±13.8

−6.60 (−15.32 to 2.13)

0.13

 Standard (n=20)

52.2±15.2

73.1±15.3

20.9±16.6

−0.09 (−1.20 to 1.02)

0.87

−2.05 (−5.11 to 1.01)

0.18

−0.51 (−4.31 to 3.29)

0.79††

−0.47 (−5.24 to 4.30)

0.85††

0.11 (−3.07 to 3.29)

0.95††

Variable

HOOS scores
HOOSPain§

HOOSSymptoms§

HOOSADL§

HOOSSport§

HOOSQOL§

PSFS, mean of up to five activities
PSFS¶
 MoveTrain (n=22)

5.8±1.9

7.5±2.2

1.7±1.7

 Standard (n=20)

5.3±1.5

7.2±2.2

1.8±1.8

 MoveTrain (n=22)

50.0±5.7

53.5±6.1

3.5±4.8

 Standard (n=20)

47.9±6.2

54.3±5.9

6.4±5.8

 MoveTrain (n=22)

53.6±5.0

46.8±7.8

−6.8±6.3

 Standard (n=20)

54.6±4.3

48.1±6.7

−6.5±6.6

 MoveTrain (n=22)

55.1±3.2

46.6±9.0

−8.4±7.5

 Standard (n=20)

55.2±2.7

47.3±8.4

−7.9±8.5

PROMIS T-scores**
PROMIS mobility

PROMIS pain interference

PROMIS pain behaviour

PROMIS global physical health
 MoveTrain (n=22)

49.7±6.1

56.1±7.4

6.4±5.4

 Standard (n=20)

49.9±5.7

56.2±6.4

6.2±5.7

PROMIS global mental health
 MoveTrain (n=22)

52.3±9.4

53.8±11.2

1.5±5.6

 Standard (n=20)

55.5±7.9

58.7±8.5

3.2±5.7

1.3±1.5
1.0±1.4

−2.9±1.5
−2.5±1.9

−1.82 (−5.47 to 1.83)

0.32

Pain numeric rating scales
Pain (average)‡‡
 MoveTrain (n=22)
 Standard (n=20)

4.1±2.0
3.5±1.5

0.21 (−0.96 to 1.38)

0.73§§
Continued
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Table 4 Continued

Variable

Pretest
Mean±SD

Post-test
Mean±SD

5.6±2.0
5.8±1.9

2.0±1.7
1.9±2.2

Within-group
change*
Mean±SD

Adjusted immediate
treatment effect†
Mean (95% CI)

P value‡

Pain (worst)‡‡
 MoveTrain (n=22)
 Standard (n=20)

−3.7±1.8
−3.9±3.0

0.36 (−0.74 to 1.46)

0.52§§

*Change is calculated by subtracting the pretest value from the post-test value.
†The adjusted treatment effect from least squares means is calculated by subtracting the MoveTrain minus
Standard at post-test and assesses the between-group difference in post-test values after adjusting for
pretest.
‡Unless otherwise indicated, p value by analysis of covariance using a generalised linear model.
§Patient-reported outcome measures with 100=no disability.
¶Patient Specific Functional Scale (PSFS) assesses the level of difficulty performing up to five activities due
to hip pain or symptoms. 0=unable to perform activity; 10=able to perform activity at preinjury level.
**PROMIS T-scores for the measures included in this study range from 20 to 80 and have a mean score of
50 and SD of 10, using the US general population as the reference. A higher score represents more of the
concept being measured. Minimally important differences (MIDs) have not been established for those with
HRGP. More information regarding PROMIS score interpretation may be found at the following website:
http://www.healthmeasures.net/score-and-interpret/interpret-scores/promis
††P value by non-parametric analysis of covariance.
‡‡Pain rated by patients using a verbal numerical pain rating scale. 0=no pain; 10=worst pain imaginable.
§§P value by analysis of covariance using multinomial generalised estimating equations with a cumulative
logit.
HOOS, Hip Disability and Osteoarthritis Outcome Score; HOOSADL, function in activities of daily living;
HOOSQOL, quality of life; HOOSSport, function in sports and recreation; HRGP, hip-related groin pain;
MoveTrain, movement pattern training group; PROMIS, Patient-Reported Outcomes Measurement
Information System.
similar treatment effects and assist in improving HEP
adherence.
We have developed methods to establish and monitor
treatment fidelity. In the future, we will use the checklist used for role-
played scenarios to monitor actual
treatment sessions. For chart reviews, we noted the two
items most often scored as insufficient included ‘review
of key concepts’ and ‘addressing barriers to HEP completion’. Discussion with treating PTs indicated they indeed
performed these tasks; however, they did not specifically
document their strategies. In the future, we will modify
treating PTs’ documentation forms to provide a specific
place to document these two key items. This addition will
serve as an improved method to ensure documentation
of protocol adherence and as a reminder to treating PTs
to perform these items.
Preliminary effectiveness
Our study was designed to assess feasibility; therefore, we
did not expect to find statistical differences in secondary
outcome measures. Both groups demonstrated similar
improvements in all patient-reported outcomes. These
findings are important because it suggests that patients
with HRGP may benefit from PT-
led intervention.
Patients in this study reported moderate activity limitations at baseline. After treatment, HOOS subscales were

substantially improved with increases of 12–24 points. No
unexpected adverse events occurred, suggesting these
interventions are safe.
After treatment, MoveTrain did demonstrate a significantly larger reduction in hip adduction and pelvic
drop during single leg squat compared with Standard,
supporting our a priori hypothesis. The goal of MoveTrain training is to improve lower extremity kinematics
during daily and patient-specific tasks. Because MoveTrain changes the way people move, stresses on joint
tissues may be altered, potentially resulting in greater
long-
term effects than Standard. Interestingly, fewer
patients in MoveTrain reported discomfort with their
exercises (table 3). We are currently collecting patient-
reported outcome measures 6 and 12 months after
treatment to determine if between-group differences
emerge over time. Further investigation is warranted to
determine if the improved movement patterns can be
sustained over time and have a protective influence on
the hip.
There were similar strength improvements, ranging
from 6% to 16%, in both patient groups. Although the
MoveTrain group did not perform traditional strengthening exercises, the functional tasks performed
MoveTrain incorporated general principles of strength
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Table 5 Summary of results for preliminary effectiveness variable (targeted impairments) (n=42)
Variable

Pretest
Mean±SD

Post-test
Mean±SD

Within-group change*
Mean±SD

Adjusted immediate
treatment effect†
Mean (95% CI)

P value‡

−7.2 (−12.9 to −1.4)

0.016

Hip kinematics for the study side (°)§
Hip adduction angle¶
 MoveTrain (n=22)

23.5±11.4

15.6±9.5

−7.9±12.5

 Standard (n=20)

16.9±11.0

19.4±11.3

2.5±7.1

Pelvic tilt excursion**
 MoveTrain (n=22)

−10.7±5.1

−7.5±4.6

3.3±5.7

 Standard (n=20)

−8.6±7.2

−9.5±5.4

−0.8±4.6

 MoveTrain (n=22)

3.8±6.6

2.8±3.9

−1.0±6.3

 Standard (n=20)

7.5±8.9

5.3±5.6

−2.2±6.3

3.0 (0.4 to 5.6)

0.026

−1.1 (−3.6 to 1.4)

0.37

0.3 (−0.9 to 1.5)

0.65

−0.2 (−0.6 to 0.3)

0.44

−0.1 (−0.6 to 0.5)

0.73

 Trunk lean excursion**

Hip muscle strength for the study side††
ABDs, torque (Nm)
 MoveTrain (n=22)

7.3±3.3

8.4±3.1

1.2±2.1

 Standard (n=20)

6.8±3.6

7.8±2.9

1.0±2.3

 MoveTrain (n=22)

2.3±1.0

2.5±0.9

0.2±0.8

 Standard (n=20)

2.3±1.1

2.7±1.1

0.4±0.7

 MoveTrain (n=22)

2.5±0.8

2.8±0.8

0.2±0.7

 Standard (n=20)

2.3±0.9

2.7±1.2

0.4±1.1

 MoveTrain (n=21)

4.4±2.0

5.3±2.4

0.9±1.3

 Standard (n=20)

4.7±3.1

5.2±2.1

0.5±1.9

 MoveTrain (n=22)

5.8±2.1

7.0±2.6

1.3±2.1

 Standard (n=19)

5.5±1.8

6.3±1.9

0.8±1.6

 MoveTrain (n=22)

8.8±4.0

9.4±4.0

0.5±2.7

 Standard (n=19)

8.9±4.4

9.9±4.4

1.0±2.3

ERs90° torque (Nm)

 IRs90° torque (Nm)

ADDs, torque (Nm)
0.2 (−0.6 to 1.1)

0.60‡‡

0.6 (−0.6 to 1.7)

0.34

−0.5 (−2.1 to 1.0)

0.51

Flexs, torque (Nm)

Exts, torque (Nm)

*Change is calculated by subtracting the pretest value from the post-test value.
†The adjusted treatment effect from least squares mean is calculated by subtracting the MoveTrain minus Standard at post-test, and
assesses the between-group difference in post-test values after adjusting for pretest.
‡Unless otherwise indicated, p value by analysis of covariance using a generalised linear model.
§Kinematics represent the mean of up to three trials where the sign of the measurements (ie, negative or positive) are included when
computing the average.
¶Hip adduction angle was measures at the lowest depth of the single leg squat. Larger positive values indicate a larger hip adduction
angle.
**Values for excursion were calculated from first initiation of descent to the end of descent on the stance leg. Pelvic tilt excursion: larger
negative values indicate a larger pelvic drop. Trunk lean: larger positive values indicate trunk lean towards the weightbearing limb.
††Muscle torque (Nm) was normalised by body weight (N) × height (m) × 100 using the mean of up to three trials.
‡‡P value by non-parametric analysis of covariance.
ABDs, abductors with the hip in 0° hip flexion, 0° abduction and 0° rotation; ADDs, adductors with the hip in 0° hip flexion, 0° abduction
and 0° rotation; ERs90°, external rotator strength with hip in 90° flexion, 0° abduction and 0° rotation; Exts, extensors with the hip in 0°
hip flexion, 0° abduction and 0° rotation; Flexs, flexors with the hip in 0° hip flexion, 0° abduction and 0° rotation; IRs90°, internal rotator
strength with hip in 90° flexion, 0° abduction and 0° rotation; MoveTrain, movement pattern training group.

training. Based on patient performance, the tasks were
progressed by level of difficulty or by increasing resistance. Therefore, these progressive activities may have
contributed to improved muscle strength.
10

Limitations
We cannot make definitive statements regarding efficacy
of MoveTrain or Standard treatment; however, our results
are promising. Improvements were reported in both
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treatment groups, and those in MoveTrain improved
their kinematics. We did not have a control group; therefore, patient improvement may be related to passage of
time. We consider this unlikely, because in our proof-
of-concept study,9 patients with HRGP randomised to a
6-week waitlist demonstrated a worsening in HOOSADL
and no improvement in other HOOS subscales compared
with baseline. Additionally, our patients reported pain
duration greater than 3 months prior to enrolling,
suggesting that time alone may not explain our results.
We must acknowledge that we have completed a number
of statistical tests, therefore increasing the likelihood
of a type I error. We identified our a priori variables of
interest and focused our discussion on results related
to these variables. However, given limited information
related to non-
operative management of HRGP, we
believe it important to report all analyses that may be
useful for future investigations. Finally, we did not establish test–retest reliability of the strength measures used in
this pilot study; however, we will include reliability testing
for the future trial.
We completed a pilot, multicentre RCT to assess our
capability of completing a larger, definitive RCT to
assess the efficacy of MoveTrain. We encountered no
major problems and have determined a full study can
proceed with modifications. Preliminary results from
this study suggests that both MoveTrain and Standard
reported outcomes;
may result in improved patient-
however, only MoveTrain resulted in improved lower
extremity kinematics. Additionally, fewer patients
reported discomfort with the exercises provided in
MoveTrain, which may influence patient adherence
to treatment. Further investigation of MoveTrain is
warranted. We do not know if the improvements in
patient-reported outcomes observed in this study were
due to the treatment provided or due to the fact that
the participants interacted with a healthcare professional. An adequately powered RCT is needed to assess
the efficacy of MoveTrain compared with an attention
control. Future work will also include the assessment of
the sustained benefits of PT-led interventions.
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